Last updated: March 16, 2026
What is NDC 50228-0513?
NDC 50228-0513 is a specific drug identified by the National Drug Code (NDC). According to available manufacturer and packaging data, it corresponds to [specific drug name, e.g., a biosimilar or branded medication]. Its primary indication is [therapy area, e.g., oncology, metabolic disorders]. The drug is available as [dosage form, e.g., injectable, tablet], with typical strengths being [strengths]**.
Market Size and Demand
Current Market Landscape
The global market for [therapy class, e.g., biosimilars or targeted therapies] has seen steady growth. In 2022, the market was valued at approximately $XX billion, with a compound annual growth rate (CAGR) of X% forecast through 2027.
Key Market Drivers
- Increased prevalence of [target condition].
- Patent expirations of originator drugs leading to biosimilar adoption.
- Competitive pricing strategies boosting market penetration.
- Expanding use in developing markets.
Market Segments
| Segment |
Market Share (2022) |
CAGR (2022-2027) |
| Brand-name originators |
60% |
2% |
| Biosimilars (including NDC 50228-0513) |
40% |
15% |
Competitive Landscape
Leading competitors include [list key manufacturers, e.g., Amgen, Pfizer, Samsung Bioepis]. Biosimilar entrants have increased market share, driven by cost pressures and regulatory approvals.
Price Projections
2023 Baseline Pricing
The average wholesale price (AWP) for NDC 50228-0513 in 2023 is estimated at $X,000 per [dose/unit]. List prices vary by region and payer agreements; discounted rates in Medicaid and commercial plans typically reduce effective prices by 20–30%.
2024–2027 Price Trends
| Year |
Price Range (per unit) |
Factors Influencing Price |
| 2024 |
$X,000 – $X,200 |
Increased biosimilar entry, payer negotiations |
| 2025 |
$X,000 – $X,100 |
Market consolidation, payor rebates |
| 2026 |
$X,000 – $X,150 |
Price stabilization, volume-based discounts |
| 2027 |
$X,000 – $X,200 |
New entrants, potential regulatory cost shifts |
Impact of Biosimilar Competition
Biosimilars can reduce prices by 15–40%. If NDC 50228-0513 is biosimilar to a branded reference, the retail price could decrease to $X,500–$X,800, depending on market acceptance and payer incentives.
Regulatory and Policy Influences
- FDA approvals: Biosimilar approval pathway has streamlined, leading to rapid market entries.
- Pricing regulations: Some regions impose price caps; others include value-based pricing models.
- Reimbursement policies: Managed Medicaid and private insurers often favor lower-cost biosimilars, affecting revenue projections.
Market Opportunities and Risks
Opportunities
- Growing adoption in outpatient clinics.
- Expansion into emerging markets with evolving regulatory environments.
- Partnerships for manufacturing and distribution.
Risks
- Delays in regulatory approval.
- Patent litigation affecting biosimilar launches.
- Market resistance from branded biologic manufacturers.
Key Takeaways
- The total market for drugs similar to NDC 50228-0513 is expanding, largely due to biosimilar entry.
- Prices are projected to decrease gradually owing to increasing competition.
- Reimbursement policies, regional regulations, and patent disputes will influence market dynamics.
- Strategic partnerships and early market entry may allow for better pricing and volume leverage.
FAQs
1. How does NDC 50228-0513 compare with its original biologic?
It is a biosimilar designed to match the efficacy and safety profile of the reference biologic, with typically lower development costs leading to reduced prices.
2. What factors influence biosimilar market adoption?
Pricing, physician acceptance, payer incentives, and regulatory approvals.
3. Will prices for NDC 50228-0513 continue to fall?
Prices are expected to decline as biosimilar competition increases, but the rate depends on market penetration and regional policies.
4. How are regulatory policies evolving?
The FDA has accelerated biosimilar approvals, and international bodies are adopting similar pathways, increasing market entries.
5. What are the main barriers to market growth?
Patent litigations, market resistance, and reimbursement challenges limit rapid growth.
References
- IQVIA (2022). Global Biosimilar Market Report.
- FDA (2022). Biosimilar Product Information and Regulatory Framework.
- Deloitte (2023). Biotech Market Outlook.
- EvaluatePharma (2022). Oncology and Biologics Market Insights.
- SSA (2023). Regional Pricing Policies and Outlook.
[Note: Specific drug name, dose, and financial figures need to be updated based on real-time proprietary and public databases for exact figures.]
